Page last updated: 2024-12-04

4-iodo-2,5-dimethoxyphenylisopropylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1229
CHEMBL ID6616
CHEBI ID64629
SCHEMBL ID293580
MeSH IDM0065620

Synonyms (55)

Synonym
gtpl147
LOPAC0_000466
DOI ,
64584-34-5
doi,(+)
chembl6616 ,
[125i]2,5-dimethoxy-4-iodoamphetamine
[125i]4-iodo-2,5-dimethoxyphenylisopropylamine
bdbm28582
doi,(-)
4-iodo-2,5-dimethoxy-alpha-methylbenzeneethanamine
4-doi
2,5-dimethoxy-4-iodoamphetamine
1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane
4-iodo-2,5-dimethoxyamphetamine
4-iodo-2,5-dimethoxyphenylisopropylamine
doi-p
1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
2,5-dimethoxy-4-iodophenylisopropylamine
benzeneethanamine, 4-iodo-2,5-dimethoxy-alpha-methyl-
PDSP2_001367
PDSP1_001383
NCGC00162163-01
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
2,5-dimethoxy 4-iodoamphetamine
NCGC00015302-04
inchi=1/c11h16ino2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7h,4,13h2,1-3h3
bgmzuekzenqujy-uhfffaoysa-
L000011
racemic doi
chebi:64629 ,
A834816
4-iodo-3-methoxy-n-(2-methoxy-1-methyl-ethyl)aniline
CCG-204558
2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine
AKOS015965128
NCGC00015302-03
oom10gw9ue ,
unii-oom10gw9ue
(+-)-doi
SCHEMBL293580
BGMZUEKZENQUJY-UHFFFAOYSA-N
(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
(+/-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane
(+/-)-doi
benzeneethanamine, 4-iodo-2,5-dimethoxy-.alpha.-methyl-
DTXSID7040520
82830-53-3
J246.190K ,
1-(4-iodo-2,5-dimethoxyphenyl)-2-propanamine
3-(4-bromo[1,1-biphenyl]-4-yl)-1,2,3,4-tetrahydro-1-naphthol
F15177
Q209251
SDCCGSBI-0050451.P002
benzeneethanamine,?4-iodo-2,5-dimethoxy-.alpha.-methyl-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It produces serious adverse effects, but its pharmacological profile is not well recognized."( Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.
Gołembiowska, K; Kamińska, K; Kreiner, G; Noworyta-Sokołowska, K; Rogóż, Z, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves of these compounds in the former were shifted to the right and/or abolished, suggesting decreased sensitivity of LEW/N hypothalami to these neurotransmitters."( Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone.
Aksentijevich, S; Bagdy, G; Bernardini, R; Calogero, AE; Chrousos, GP; Gold, PW; Smith, C; Sternberg, EM; Wilder, RL, 1992
)
0.28
" Results from a dose-response experiment indicate that increasing the dose of 5-HT can transform an inhibitory response into a biphasic or even an excitatory response."( Electrophysiological analyses of serotonergic actions on neurons in hypothalamic ventromedial nucleus in vitro: receptor subtypes involved and implications for regulation of feeding and lordosis behaviors.
Kow, LM; Pfaff, DW; Tsai, YF; Wang, L, 1992
)
0.28
" We performed acute dose-response and time course behavioral studies in 1-day-old rats with the putative selective agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (5-HT1A), 5-methoxy-3(1,2,3,6-tetrahydropyridin-4-yl)1H-indole (RU 24969) (5-HT1B), and (+-)1-(2,5-dimethoxy-4-iodo-phenyl aminopropane)-2 (DOI) (5-HT2/1C)."( Serotonin receptor ontogeny: effects of agonists in 1-day-old rats.
Pranzatelli, MR, 1992
)
0.28
" The enhanced attenuation of responses to noxious colorectal distension produced by the coadministration of these drugs is evidenced by significant leftward shifts in the dose-response curves as compared to those of each drug alone and by isobolographic analysis."( Intrathecal coadministration of clonidine with serotonin receptor agonists produces supra-additive visceral antinociception in the rat.
Danzebrink, RM; Gebhart, GF, 1991
)
0.28
"8 mg/kg, was fatal in 4 of 5 MH-susceptible pigs, whereas pigs injected with this dosage after pretreatment with ketanserin (0."( Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.
Bickhardt, K; Fredow, G; Ganter, M; Löscher, W; Witte, U, 1990
)
0.28
" These behaviors had a similar dose-response and time course and were blocked by the 5-HT2/5-HT1C antagonists mianserin, ritanserin, and methysergide."( Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI).
Pranzatelli, MR, 1990
)
0.28
" LY 53857, significantly and dose dependently shifted to the right the dose-response curves to both 5-HT and DOI."( Characterization of DOI, a putative 5-HT2 receptor agonist in the rat.
Chaouche-Teyara, K; Cherqui, C; Dabiré, H; Fournier, B; Laubie, M; Schmitt, H, 1989
)
0.28
" The dose-response curve for 5-HT was shifted 9-fold to the left compared to controls, and the Vmax value was also significantly enhanced."( Dexamethasone potentiates serotonin-2 receptor-mediated intracellular Ca2+ mobilization in C6 glioma cells.
Kagaya, A; Mikuni, M; Muraoka, S; Saitoh, K; Takahashi, K, 1993
)
0.29
" The decrease in 5-HT turnover more closely correlated with the dose-response curve for loss of righting reflex, a behavioral measure of hypnosis, than did the norepinephrine turnover."( Role of serotonergic neurotransmission in the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist.
Gregg, K; Guo, TZ; Maze, M; Rabin, BC, 1996
)
0.29
" The dose-response experiment revealed that little Fos-like immunoreactivity was evident above basal levels following administration of 1 mg/kg DOI."( Paradoxical effects of lithium on serotonergic receptor function: an immunocytochemical, behavioural and autoradiographic study.
Leslie, RA; Moorman, JM, 1998
)
0.3
" Dose-response studies of 8-OH-DPAT and DOI alone and in the presence of selected doses of the other drug were performed in order to allow isobolographic analysis, which characterizes the relationship of two drugs as either additive (no interaction), supra-additive, or infra-additive."( Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats.
Geyer, MA; Krebs-Thomson, K, 1998
)
0.3
" The present experiments were performed in order to study the effects of acute treatment with low doses of melatonin on rat male and female sex behavior in a dose-response paradigm."( Acute low doses of melatonin stimulate rat sex behavior: the role of serotonin neurotransmission.
Benelli, A; Bertolini, A; Busà, L; Drago, F, 1999
)
0.3
" The desensitization was dose-dependent, and it shifted the oxytocin and ACTH dose-response curves of 8-OH-DPAT to the right (increased ED(50)) with no change in their maximal responses (E(max))."( Characterization of the functional heterologous desensitization of hypothalamic 5-HT(1A) receptors after 5-HT(2A) receptor activation.
Battaglia, G; D'Souza, D; Garcia, F; Muma, NA; Raap, DK; Van de Kar, LD; Zhang, Y, 2001
)
0.31
" Initially, we established a dose-response relationship for the acute and chronic haloperidol and DOI-induced HTR."( Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome.
Hayslett, RL; Tizabi, Y, 2005
)
0.33
" To probe the role of 5-HT2R in this increased amplitude, dose-response studies were done with the selective antagonists mianserin or LY53857 and the 5-HT2R agonist (+/-)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI)."( Up-regulation of 5-HT2 receptors is involved in the increased H-reflex amplitude after contusive spinal cord injury.
Johnson, CS; Lee, JK; Wrathall, JR, 2007
)
0.34
"25-1 mg/kg) did not alter the dose-response curve of nicotine, while DOI (0."( Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
Filip, M; McCreary, AC; Przegaliński, E; Zaniewska, M, 2007
)
0.34
" Oral dosing of AR246686 to rats resulted in prolongation of time to occlusion at 1 mg/kg, whereas increased bleeding time was observed at a dose of 20 mg/kg."( Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist.
Adams, JW; Al-Shamma, H; Behan, DP; Connolly, DT; Dosa, P; Morgan, M; Ortuno, D; Ramirez, J; Richman, JG; Shi, Y; Teegarden, BR; Thomsen, W, 2008
)
0.35
" In combination tests, both agonists shifted the dose-response curve of LSD leftward, most potently for the LSD-90 cue."( Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.
Chemel, BR; Marona-Lewicka, D; Nichols, DE, 2009
)
0.35
"0 mg/kg) was coadministered with saline or different cocaine doses, we observed similar upward shifts in dose-response in both phenotypes."( Reduced sensitivity to the locomotor-stimulant effects of cocaine is associated with increased sensitivity to its discriminative stimulus properties.
Gulley, JM; Klein, DA, 2009
)
0.35
" DOI produced an inverted U-shaped dose-response function, with lower doses (0."( 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice.
Geyer, MA; Gingrich, JA; Halberstadt, AL; Powell, SB; Risbrough, VB; Ruderman, MA; van der Heijden, I, 2009
)
0.35
" The effects of the phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) on head-twitch behavior were studied over a range of doses in the mouse, generating a characteristic biphasic dose-response curve."( Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.
Cohen, MS; Fantegrossi, WE; Henson, CM; Rice, KC; Simoneau, J; Woods, JH; Zimmerman, SM, 2010
)
0.36
" In this work, dose-response curves (0."( Behavioral profiles in rats distinguish among "ecstasy," methamphetamine and 2,5-dimethoxy-4-iodoamphetamine: Mixed effects for "ecstasy" analogues.
Cassels, BK; Díaz-Véliz, G; Mora-Gutiérrez, S; Quinteros-Muñoz, D; Rebolledo-Fuentes, M; Sáez-Briones, P, 2010
)
0.36
" In a dose-response study the 5-HT2A agonist (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) (25 nM to 5 μM) protected against serum deprivation cytotoxicity."( 5-HT2A serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: role of the ERK pathway.
Grünblatt, E; Marinova, Z; Walitza, S, 2013
)
0.39
"The repeated administration of methamphetamine (MA) to animals in a single-day 'binge' dosing regimen produces damage to dopamine and serotonin terminals and psychosis-like behaviours similar to those observed in MA abusers."( Long-lasting alterations in 5-HT2A receptor after a binge regimen of methamphetamine in mice.
Chan, MH; Chen, HH; Chen, ST; Chiu, HY; Lee, MY; Zhan, ZY, 2014
)
0.4
"2 mg/kg) increased the GBO power, exhibiting an inverted U-shape dose-response curve; at higher doses (0."( Differential effects of NMDA receptor antagonists at lower and higher doses on basal gamma band oscillation power in rat cortical electroencephalograms.
Chaki, S; Hiyoshi, T; Kambe, D; Karasawa, J, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency0.37930.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
Ataxin-2Homo sapiens (human)Potency35.48130.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.02450.00020.667710.0000AID4762; AID5263
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.01290.00010.601710.0000AID1442357; AID1442358; AID1442359; AID385347; AID5263
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki1.72330.00000.385510.0000AID1442359; AID389734; AID389735; AID408464; AID408465; AID408466; AID408467; AID5186
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.00180.00010.954910.0000AID5866
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.01900.00020.590910.0000AID5263
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.00320.00011.18738.9125AID1285658; AID1336357; AID1433981; AID346454; AID751852; AID752215
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.01040.00030.769310.0000AID1433981; AID346454; AID5762; AID611935; AID751852
5-hydroxytryptamine receptor 5AHomo sapiens (human)Ki1.00000.00080.94335.1600AID6479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Kd5.01190.00010.95285.0119AID438555
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)EC50 (µMol)0.17800.00180.05350.1780AID1446100
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd0.03240.00042.58328.5114AID6405
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)EC50 (µMol)0.05700.00010.49294.0000AID1446099
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd0.03240.00012.62198.5114AID6405
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd0.03240.00012.29338.5114AID6405
5-hydroxytryptamine receptor 2AHomo sapiens (human)EC50 (µMol)0.00630.00000.22763.4750AID1232237
5-hydroxytryptamine receptor 2CHomo sapiens (human)EC50 (µMol)0.04570.00010.10082.4500AID1232238
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd0.03240.00042.47358.5114AID6405
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd0.03240.00012.70068.5114AID6405
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd0.03240.00082.62148.5114AID6405
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd0.03240.02342.74218.5114AID6405
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd0.03240.00082.62148.5114AID6405
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)K aff0.04300.04300.04300.0430AID5676
5-hydroxytryptamine receptor 2AMus musculus (house mouse)K aff0.11900.11900.11900.1190AID5443
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (89)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
hippocampus development5-hydroxytryptamine receptor 5AHomo sapiens (human)
response to estradiol5-hydroxytryptamine receptor 5AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 5AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 5AHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
perikaryon5-hydroxytryptamine receptor 5AHomo sapiens (human)
postsynaptic specialization membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 5AHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (164)

Assay IDTitleYearJournalArticle
AID1446100Agonist activity at rat 5-HT2C receptor expressed in African clawed frog oocytes assessed as increase in current amplitude2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.
AID192235Percentage of animals emitting >80% of lever presses in rats at a compound dose of 0.28 uM/Kg1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID14353The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID197318Concentration required to produce DOM like response when administered in rats1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID178730Effective dose in rat1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID197285Number of animals responding to the drug 1.2 (mg/kg) out of 3 animals tested1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID6479Binding affinity towards human 5-hydroxytryptamine 5A receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID1442358Displacement of [3H]DOB from 5HT2A in Sprague-Dawley rat cortex membranes measured after 15 mins by scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID176716Dose at which the rats perform 50% appropriate drug -lever responding was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID14357The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID5676Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID751852Binding affinity to human 5-HT2B receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID408467Displacement of [3H]INBMeO from human 5HT2A receptor expressed in human HEK293 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID190259The percentage of rats selecting the drug lever at each dose1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID14347The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID231965Ratio of distribution of the [131I]-labeled compound at 5 min in rat kidney over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID408464Displacement of [3H]ketanserin from human 5HT2A receptor expressed in human A549 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID14348The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID4762Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID14195The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID101152Evaluated in the two-lever drug discrimination assay in LSD trained rats to assess hallucinogenic-like activity (95% confidence intervals)2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
AID175378Percentage of animals failing to emit 50 lever presses within 15 min in rats at a compound dose of 0.4 mg/kg1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID6405Binding affinity at rat 5-hydroxytryptamine receptor.1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID5866Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
AID177676Effective concentration required to determined hallucinogen-like activity in LSD-trained rats2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties.
AID178391Effective dose for drug discrimination assay in rats using DOI as training drug.1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).
AID438555Binding affinity to 5HT1A receptor2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Physical binding pocket induction for affinity prediction.
AID346454Displacement of radiolabeled DOI from human 5HT2B receptor agonist site2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1232239Selectivity for human 5-HT2A receptor over human 5-HT2C receptor by IP-One assay2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
AID408466Displacement of [3H]ketanserin from human 5HT2A receptor expressed in human HEK293 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID231967Ratio of distribution of the [131I]-labeled compound at 5 min in rat lung over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID188586Number of rats responding out of 5 treated rats at a dose of 1 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID1336357Displacement of [125I]DOI from human recombinant 5HT2B receptor expressed in CHO cells measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID197284Number of animals responding to the drug 0.5 (mg/kg) out of 3 animals tested1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID3192Efficacy against 5-hydroxytryptamine 2A receptor1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID14346The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID14191The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID1446099Agonist activity at rat 5-HT2A receptor expressed in African clawed frog oocytes assessed as increase in current amplitude2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.
AID752215Binding affinity to human 5-HT2B receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID5095Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID408465Displacement of [3H]INBMeO from human 5HT2A receptor expressed in human A549 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID14198The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID5680The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID231960Ratio of distribution of the [131I]-labeled compound at 30 min in rat kidney over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID3696Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID175236Percentage of animals failing to emit 50 lever presses within 15 min in rats at a compound dose of 0.1 mg/kg1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID5099Hill coefficient of compound was determined1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID188583Number of rats responding out of 5 treated rats at a dose of 0.25 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID192236Percentage of animals emitting >80% of lever presses in rats at a compound dose of 0.56 uM/Kg1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID14352The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID5186Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
AID189902Percentage of rats selecting the drug liver at dose of 0.2 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID189900Percentage of rats selecting the drug liver at dose of 0.1 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID1433981Displacement of [125I](+/-)DOI from human recombinant 5-HT2B receptor expressed in CHO cells after 60 mins by scintillation counting2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.
AID2330285-HT1C selectivity was defined as the ratio between Ki(5-HT2)/Ki(5-HT1C)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID231964Ratio of distribution of the [131I]-labeled compound at 5 min in rat heart over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID188584Number of rats responding out of 5 treated rats at a dose of 0.5 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID5445The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID389734Displacement of [3H]ketanserin from 5HT2A receptor expressed in NIH3T3 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
AID14350The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID192237Percentage of animals emitting >80% of lever presses in rats at a compound dose of 1.12 uM/Kg1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID189904Percentage of rats selecting the drug liver at dose of 0.4 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID176658Substitution tests were carried out for the compound in LSD- trained rats dosed with 0.02 mg/kg drug and the binding data was reported1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID1232241Partial agonist activity at human 5-HT2C receptor expressed in HEK293 cells preincubated for 1 hr at 37 degC followed by incubated for 15 mins at room temperature by IP-One assay relative to 5-HT2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
AID1232237Partial agonist activity at human 5-HT2A receptor expressed in HEK293 cells preincubated for 1 hr at 37 degC followed by incubated for 15 mins at room temperature by IP-One assay2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
AID175377Percentage of animals failing to emit 50 lever presses within 15 min in rats at a compound dose of 0.2 mg/kg1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID175415Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 0.25 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID389735Displacement of [3H]ketanserein from 5HT2A receptor F340L mutant expressed in NIH3T3 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
AID197484DOM appropriate responses per min when compound administered at 1.8 mg/kg1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID197286Number of animals responding to the drug 1.8 (mg/kg) out of 3 animals tested1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID14196The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID197482DOM appropriate responses per min when compound administered at 0.5 mg/kg1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID385347Displacement of [3H]ketanserin from 5HT2A receptor in Sprague-Dawley rat brain by liquid scintillation spectroscopy2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID5093Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID175416Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 0.5 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID5097Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID14192The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID5299Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID1442359Displacement of [125I]DOI from recombinant human 5HT2A expressed in Syrian hamster AV12 cell membranes2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID231966Ratio of distribution of the [131I]-labeled compound at 5 min in rat liver over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID14356The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID4388Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
AID5263Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID14351The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID197282DOM appropriate responding in percent when compound administered at 1.2 mg/kg1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID177091Drug discrimination studies in rats(12) expressed as ED50 value1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
AID197483DOM appropriate responses per min when compound administered at 1.2 mg/kg1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID14194The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID14354The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID175418Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 0.75 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID1442357Displacement of [3H]ketanserin from 5HT2A in Sprague-Dawley rat cortex membranes measured after 15 mins2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID611935Displacement of [125I](+/-)-DOI from human 5HT2B receptor2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID175419Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 1 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID57528Evaluated in the two-lever drug discrimination assay in DOI trained rats to assess hallucinogenic-like activity (95% confidence intervals)2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
AID1232238Partial agonist activity at human 5-HT2C receptor expressed in HEK293 cells preincubated for 1 hr at 37 degC followed by incubated for 15 mins at room temperature by IP-One assay2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
AID231963Ratio of distribution of the [131I]-labeled compound at 5 min in rat brain over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID1285658Displacement of [125I](+/-)DOI from human recombinant 5-HT2B receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID5762Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
AID231961Ratio of distribution of the [131I]-labeled compound at 30 min in rat liver over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID385349Lipophilicity of compound by immobilized artificial membrane column containing phosphatidylcholine head groups HPLC2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID241440Inhibitory concentration against monoamine oxidase A in rat brain mitochondrial suspension2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling.
AID176659Substitution tests were carried out for the compound in LSD- trained rats dosed with 0.046 uM/kg drug and the binding data was reported1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID188585Number of rats responding out of 5 treated rats at a dose of 0.75 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID89084Hallucinogenic potency was determined in humans1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID385350Agonist activity at Sprague-Dawley rat 5HT2A receptor by drug discrimination assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID14193The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID14197The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID1446101Agonist activity at rat 5-HT2A receptor expressed in African clawed frog oocytes assessed as increase in current amplitude relative to 5-HT2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.
AID197281DOM appropriate responding in percent when compound administered at 0.5 mg/kg1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID231959Ratio of distribution of the [131I]-labeled compound at 30 min in rat heart over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID231962Ratio of distribution of the [131I]-labeled compound at 30 min in rat lung over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID1446102Agonist activity at rat 5-HT2C receptor expressed in African clawed frog oocytes assessed as increase in current amplitude relative to 5-HT2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.
AID231958Ratio of distribution of the [131I]-labeled compound at 30 min in rat brain over uptake in blood1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID14349The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID197283DOM appropriate responding in percent when compound administered at 1.8 mg/kg1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID5226Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors.
AID14355The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
AID5443Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID1232240Partial agonist activity at human 5-HT2A receptor expressed in HEK293 cells preincubated for 1 hr at 37 degC followed by incubated for 15 mins at room temperature by IP-One assay relative to 5-HT2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
AID1346903Rat 5-HT2B receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)1990Molecular pharmacology, Nov, Volume: 38, Issue:5
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A1996Biochemical pharmacology, Jan-12, Volume: 51, Issue:1
Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2003British journal of pharmacology, Sep, Volume: 140, Issue:2
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2003British journal of pharmacology, Sep, Volume: 140, Issue:2
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A1990Molecular pharmacology, Nov, Volume: 38, Issue:5
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)1996Biochemical pharmacology, Jan-12, Volume: 51, Issue:1
Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)2000Molecular pharmacology, Nov, Volume: 58, Issue:5
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
AID624240Agonists at Rat 5-Hydroxytryptamine receptor 5-HT2B1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B2003British journal of pharmacology, Sep, Volume: 140, Issue:2
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID624240Agonists at Rat 5-Hydroxytryptamine receptor 5-HT2B1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID624233Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346903Rat 5-HT2B receptor (5-Hydroxytryptamine receptors)1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2003British journal of pharmacology, Sep, Volume: 140, Issue:2
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
AID624234Agonists at Rat 5-Hydroxytryptamine receptor 5-HT2A2000Molecular pharmacology, Nov, Volume: 58, Issue:5
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
AID493017Wombat Data for BeliefDocking2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (827)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (3.39)18.7374
1990's364 (44.01)18.2507
2000's279 (33.74)29.6817
2010's145 (17.53)24.3611
2020's11 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.09 (24.57)
Research Supply Index6.74 (2.92)
Research Growth Index5.65 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.12%)5.53%
Reviews4 (0.47%)6.00%
Case Studies1 (0.12%)4.05%
Observational0 (0.00%)0.25%
Other837 (99.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]